The transcriptomic, proteomic, and metabolomics data of GBM in the orexin-treated and control groups have been measured, and significant differentially expressed molecules have been identified at each omics level caused by Orexin A, which could well identify whether GBM cells were treated with OXA or not. The gene discussed is HCRT; the disease is glioblastoma.